Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Shanthi Rexaline

What Is RSV, And Why Is Pfizer Paying Up To $525M For Treatment Candidates?

Pharma giant Pfizer, Inc. (NYSE:PFE), which has found huge success with its COVID franchise, is now looking to conquer another frontier. The company announced a deal Thursday to buy privately held biopharma ReViral, which has a portfolio of antiviral therapeutic candidates, for up to $525 million.

What's RSV: Respiratory syncytial virus, or RSV, is a common respiratory virus causing mild, cold-like symptoms, according to the Centers for Disease Control and Prevention.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.